Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Sanara MedTech Inc.NASDAQ: SMTI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $458.6K, compared with -$3.53M a year earlier. Trailing-twelve-month net income was -$23.67M. Over 3 fiscal years it compounded at +50.6% a year.
Context
- Net income amounted to 26.8% of revenue in FY2025, up 15.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $646.73K (+102.3%) for the fiscal year ending Dec 2026, a slowdown from the +179.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $458.6K+102.0% QoQ
- Last fiscal yearDec 2025
- -$27.66M+179.0% YoY
- LTMMar 2026
- -$23.67M+103.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +113.0% | -89.1% | -202.1 pp |
| 1 year | +179.0% | +102.3% | -76.7 pp |
| 3-year CAGR | +50.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (27.66M) USD
- Year-over-year change
- -179.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.66M) | -179.0% |
| FY2024 | 2024-12-31 | (9.91M) | -123.2% |
| FY2023 | 2023-12-31 | (4.44M) | +45.1% |
| FY2022 | 2022-12-31 | (8.09M) | -1.2% |
| FY2021 | 2021-12-31 | (7.99M) | — |
Net Income vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +103.8% is the 4th highest of 10, against a peer median of +21.1%.
- Net income amounts to 22.0% of revenue for SMTI, versus a peer median of 6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $166.12M USD | -770.3% | +15.0% | 2895.1% | |
| LTM Jun 2026 | $51.88M USD | -50.1% | -9.2% | 6.8% | |
| LTM Apr 2026 | CA$46.43M CAD | +388.6% | -10.1% | 6.9% | |
| LTM Mar 2026 | $37.25M USD | -24.6% | -23.6% | 46.8% | |
| LTM Mar 2026 | $23.67M USD | +103.8% | +50.6% | 22.0% | |
| LTM Mar 2026 | $21.68M USD | -14.5% | +5.8% | 69.5% | |
| LTM Mar 2026 | $20.17M USD | +30.0% | -25.1% | 29.5% | |
| LTM Mar 2026 | $16.51M USD | +191.1% | -35.0% | 4.8% | |
| LTM Mar 2026 | $15.16M USD | +21.1% | +33.9% | 5.3% | |
| LTM Mar 2026 | $507.37K USD | +105.0% | — | 0.2% | |
| Peer median (excluding SMTI) | — | +21.1% | -9.7% | 6.9% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.99M) | (8.09M) | (4.44M) | (9.91M) | (27.66M) |
| Depreciation & Amortization | 596.98K | 2.37M | 3.68M | 4.92M | 28.56M |
| Deferred Income Tax | 0 | (5.84M) | 0 | 0 | 0 |
| Stock-Based Compensation | 2.67M | 2.7M | 3.44M | 4.44M | 718.71K |
| Change in Working Capital | (1.18M) | 517.62K | (3.28M) | (911.72K) | (3.84M) |
| Accounts Receivables | (774.81K) | (2.27M) | (1.73M) | (4.54M) | 4.03M |
| Inventory | (1.15M) | (517.27K) | (1.55M) | 1.44M | (431.33K) |
| Accounts Payables | 99.13K | (423.75K) | 575.15K | (471.21K) | 1.24M |
| Other Working Capital | 645.56K | 3.73M | (577.32K) | 2.66M | (8.68M) |
| Other Non-Cash Items | 1.1M | 2.79M | (2.64M) | 1.44M | 9.02M |
| Operating Cash Flow | (4.81M) | (5.55M) | (3.25M) | (23.78K) | 6.79M |
| Capital Expenditures | (750.45K) | (747.02K) | (265.25K) | (229.3K) | (4.63M) |
| Acquisitions (Net) | 0 | (2.52M) | (9.94M) | 0 | 0 |
| Purchases of Investments | (4.53M) | (250K) | 0 | (5.3M) | 9.48M |
| Sales of Investments | 0 | 0 | 0 | 0 | (2.96M) |
| Other Investing Activities | (578.59K) | (598.45K) | 650 | (1.1M) | (10.47M) |
| Investing Cash Flow | (5.28M) | (3.51M) | (10.21M) | (6.61M) | (8.36M) |
| Debt Repayment | 0 | 0 | 9.69M | 19.59M | 0 |
| Common Stock Issued | 28.94M | 0 | 911.37K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (642.53K) | (627.35K) | (958.59K) | (2.15M) | (8.48M) |
| Financing Cash Flow | 28.3M | (627.35K) | 9.64M | 17.37M | (8.48M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 18.2M | (9.69M) | (3.81M) | 10.73M | (10.03M) |
| Free Cash Flow | (5.56M) | (6.3M) | (3.51M) | (253.08K) | 2.16M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.